Completed PHASE2 INTERVENTIONAL 1-arm NCT00083226

Doxorubicin and Bortezomib in Treating Patients With Liver Cancer

A Phase II Trial of Bortezomib Plus Doxorubicin in Hepatocellular Carcinoma

Sponsor: National Cancer Institute (NCI)

Conditions Adult Primary Hepatocellular Carcinoma Advanced Adult Primary Liver Cancer Localized Unresectable Adult Primary Liver Cancer Recurrent Adult Primary Liver Cancer

Interventions bortezomib doxorubicin

Updated 6 times since 2017 Last updated: Oct 24, 2014 Started: Mar 31, 2004 Primary completion: Feb 28, 2011 Completion: Aug 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Adult Primary Hepatocellular Carcinoma and Advanced Adult Primary Liver Cancer and is currently completed. National Cancer Institute (NCI) leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States